FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991531726> ?p ?o ?g. }

• W1991531726 endingPage "186" @default.
• W1991531726 startingPage "180" @default.
• W1991531726 abstract "Abciximab and eptifibatide have been shown to reduce ischemic complications compared with heparin alone in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Whether 1 agent is safer and/or more effective has not been prospectively examined. The aim of this study was to assess the outcomes related to downstream glycoprotein IIb/IIIa inhibitor treatment selection during percutaneous coronary intervention in 2,211 patients with moderate and high-risk acute coronary syndromes in the prospective multicenter Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. The protocol permitted operator selection of abciximab (n = 835) or eptifibatide (n = 1,376) for routine use in the trial. Multivariate and propensity-based adjustments were used to assess the independent association of glycoprotein IIb/IIIa inhibitor treatment selection with prespecified study end points. Compared to patients receiving eptifibatide, those administered abciximab were older, more likely to be enrolled outside of North America, more frequently had biomarker elevations and ST-segment deviation, but had fewer baseline cardiac risk factors and previous revascularization procedures. After multivariate propensity-based adjustment, abciximab was independently associated with significantly fewer net clinical adverse events (odds ratio 0.61, 95% confidence interval 0.42 to 0.90, p = 0.01), mediated by composite ischemia (odds ratio 0.61, 95% confidence interval 0.38 to 0.98, p = 0.04) and major bleeding (odds ratio 0.58, 95% confidence interval 0.34 to 1.00, p = 0.051). In conclusion, in this prespecified but nonrandomized comparison in patients with acute coronary syndromes who underwent percutaneous coronary intervention with catheterization laboratory initiation of glycoprotein IIb/IIIa inhibitors, the use of abciximab rather than eptifibatide was associated with improved clinical outcomes at 30 days. These findings should be viewed as exploratory in light of the nonrandomized and heterogenous nature of the comparator groups and significant potential for residual confounding. Abciximab and eptifibatide have been shown to reduce ischemic complications compared with heparin alone in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Whether 1 agent is safer and/or more effective has not been prospectively examined. The aim of this study was to assess the outcomes related to downstream glycoprotein IIb/IIIa inhibitor treatment selection during percutaneous coronary intervention in 2,211 patients with moderate and high-risk acute coronary syndromes in the prospective multicenter Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. The protocol permitted operator selection of abciximab (n = 835) or eptifibatide (n = 1,376) for routine use in the trial. Multivariate and propensity-based adjustments were used to assess the independent association of glycoprotein IIb/IIIa inhibitor treatment selection with prespecified study end points. Compared to patients receiving eptifibatide, those administered abciximab were older, more likely to be enrolled outside of North America, more frequently had biomarker elevations and ST-segment deviation, but had fewer baseline cardiac risk factors and previous revascularization procedures. After multivariate propensity-based adjustment, abciximab was independently associated with significantly fewer net clinical adverse events (odds ratio 0.61, 95% confidence interval 0.42 to 0.90, p = 0.01), mediated by composite ischemia (odds ratio 0.61, 95% confidence interval 0.38 to 0.98, p = 0.04) and major bleeding (odds ratio 0.58, 95% confidence interval 0.34 to 1.00, p = 0.051). In conclusion, in this prespecified but nonrandomized comparison in patients with acute coronary syndromes who underwent percutaneous coronary intervention with catheterization laboratory initiation of glycoprotein IIb/IIIa inhibitors, the use of abciximab rather than eptifibatide was associated with improved clinical outcomes at 30 days. These findings should be viewed as exploratory in light of the nonrandomized and heterogenous nature of the comparator groups and significant potential for residual confounding." @default.
• W1991531726 created "2016-06-24" @default.
• W1991531726 creator A5014043242 @default.
• W1991531726 creator A5016139987 @default.
• W1991531726 creator A5019656474 @default.
• W1991531726 creator A5023436129 @default.
• W1991531726 creator A5026063033 @default.
• W1991531726 creator A5030343009 @default.
• W1991531726 creator A5039632207 @default.
• W1991531726 creator A5045761776 @default.
• W1991531726 creator A5046629853 @default.
• W1991531726 creator A5050863307 @default.
• W1991531726 creator A5058875978 @default.
• W1991531726 creator A5062843291 @default.
• W1991531726 creator A5063816519 @default.
• W1991531726 creator A5064619184 @default.
• W1991531726 creator A5074461963 @default.
• W1991531726 creator A5077534264 @default.
• W1991531726 date "2010-07-01" @default.
• W1991531726 modified "2023-09-29" @default.
• W1991531726 title "Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)" @default.
• W1991531726 cites W1435359176 @default.
• W1991531726 cites W1586038305 @default.
• W1991531726 cites W1998287296 @default.
• W1991531726 cites W2012242037 @default.
• W1991531726 cites W2026202162 @default.
• W1991531726 cites W2034690624 @default.
• W1991531726 cites W2085413583 @default.
• W1991531726 cites W2088434328 @default.
• W1991531726 cites W2093117607 @default.
• W1991531726 cites W2109691078 @default.
• W1991531726 cites W2121251309 @default.
• W1991531726 cites W2122703802 @default.
• W1991531726 cites W2144829626 @default.
• W1991531726 cites W2157123954 @default.
• W1991531726 cites W2161356389 @default.
• W1991531726 cites W2330351728 @default.
• W1991531726 cites W2403069929 @default.
• W1991531726 cites W3022148767 @default.
• W1991531726 cites W4205805944 @default.
• W1991531726 cites W4233610480 @default.
• W1991531726 cites W4254730674 @default.
• W1991531726 doi "https://doi.org/10.1016/j.amjcard.2010.03.015" @default.
• W1991531726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20599000" @default.
• W1991531726 hasPublicationYear "2010" @default.
• W1991531726 type Work @default.
• W1991531726 sameAs 1991531726 @default.
• W1991531726 citedByCount "1" @default.
• W1991531726 countsByYear W19915317262013 @default.
• W1991531726 crossrefType "journal-article" @default.
• W1991531726 hasAuthorship W1991531726A5014043242 @default.
• W1991531726 hasAuthorship W1991531726A5016139987 @default.
• W1991531726 hasAuthorship W1991531726A5019656474 @default.
• W1991531726 hasAuthorship W1991531726A5023436129 @default.
• W1991531726 hasAuthorship W1991531726A5026063033 @default.
• W1991531726 hasAuthorship W1991531726A5030343009 @default.
• W1991531726 hasAuthorship W1991531726A5039632207 @default.
• W1991531726 hasAuthorship W1991531726A5045761776 @default.
• W1991531726 hasAuthorship W1991531726A5046629853 @default.
• W1991531726 hasAuthorship W1991531726A5050863307 @default.
• W1991531726 hasAuthorship W1991531726A5058875978 @default.
• W1991531726 hasAuthorship W1991531726A5062843291 @default.
• W1991531726 hasAuthorship W1991531726A5063816519 @default.
• W1991531726 hasAuthorship W1991531726A5064619184 @default.
• W1991531726 hasAuthorship W1991531726A5074461963 @default.
• W1991531726 hasAuthorship W1991531726A5077534264 @default.
• W1991531726 hasConcept C126322002 @default.
• W1991531726 hasConcept C156957248 @default.
• W1991531726 hasConcept C164705383 @default.
• W1991531726 hasConcept C17923572 @default.
• W1991531726 hasConcept C188816634 @default.
• W1991531726 hasConcept C2777698277 @default.
• W1991531726 hasConcept C2777849778 @default.
• W1991531726 hasConcept C2777871224 @default.
• W1991531726 hasConcept C2780400711 @default.
• W1991531726 hasConcept C2781056559 @default.
• W1991531726 hasConcept C44249647 @default.
• W1991531726 hasConcept C45393284 @default.
• W1991531726 hasConcept C500558357 @default.
• W1991531726 hasConcept C71924100 @default.
• W1991531726 hasConceptScore W1991531726C126322002 @default.
• W1991531726 hasConceptScore W1991531726C156957248 @default.
• W1991531726 hasConceptScore W1991531726C164705383 @default.
• W1991531726 hasConceptScore W1991531726C17923572 @default.
• W1991531726 hasConceptScore W1991531726C188816634 @default.
• W1991531726 hasConceptScore W1991531726C2777698277 @default.
• W1991531726 hasConceptScore W1991531726C2777849778 @default.
• W1991531726 hasConceptScore W1991531726C2777871224 @default.
• W1991531726 hasConceptScore W1991531726C2780400711 @default.
• W1991531726 hasConceptScore W1991531726C2781056559 @default.
• W1991531726 hasConceptScore W1991531726C44249647 @default.
• W1991531726 hasConceptScore W1991531726C45393284 @default.
• W1991531726 hasConceptScore W1991531726C500558357 @default.
• W1991531726 hasConceptScore W1991531726C71924100 @default.
• W1991531726 hasIssue "2" @default.
• W1991531726 hasLocation W19915317261 @default.
• W1991531726 hasLocation W19915317262 @default.
• W1991531726 hasOpenAccess W1991531726 @default.

• next